RapidAI vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
RapidAI's platform is used by 2,500+ hospitals in 100+ countries; received 5 new FDA clearances in Nov 2025; $75M Series C; gold standard in 75% of U.S. Comprehensive Stroke Centers.
About
RapidAI is a San Francisco-based healthcare AI company that develops clinical imaging analysis and workflow software for neurovascular, cardiac, and vascular diseases. The company originated from research at the Stanford Stroke Center and pioneered AI-powered CT perfusion analysis for ischemic stroke treatment decisions — providing physicians with automated, quantitative imaging assessments within minutes of a patient arriving at the hospital. Its technology enables faster, more consistent treatment decisions for time-critical conditions where every minute of delay increases irreversible brain damage.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.